LeMaitre Vascular Inc (NASDAQ:LMAT)’s share price reached a new 52-week high and low during trading on Tuesday . The stock traded as low as $41.19 and last traded at $41.10, with a volume of 35665 shares trading hands. The stock had previously closed at $40.90.
LMAT has been the subject of several research reports. BidaskClub downgraded LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 27th. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Thursday, December 28th. Canaccord Genuity restated a “hold” rating and set a $33.00 price objective on shares of LeMaitre Vascular in a research report on Friday, February 23rd. Finally, ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday, April 4th. Four research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $34.00.
The company has a market cap of $776.07, a P/E ratio of 47.38, a P/E/G ratio of 2.75 and a beta of 0.54.
The firm also recently declared a quarterly dividend, which was paid on Thursday, April 5th. Investors of record on Thursday, March 22nd were issued a dividend of $0.07 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.06. This represents a $0.28 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date was Wednesday, March 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 32.56%.
In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 30,000 shares of the business’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $36.19, for a total value of $1,085,700.00. Following the sale, the chairman now directly owns 3,180,709 shares in the company, valued at $115,109,858.71. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 5,700 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total value of $202,692.00. Following the completion of the sale, the chief executive officer now owns 3,259,263 shares in the company, valued at $115,899,392.28. The disclosure for this sale can be found here. Insiders have sold 137,736 shares of company stock worth $4,866,186 over the last quarter. 23.70% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Comerica Bank raised its stake in shares of LeMaitre Vascular by 53.0% in the fourth quarter. Comerica Bank now owns 35,795 shares of the medical instruments supplier’s stock valued at $1,234,000 after buying an additional 12,400 shares during the period. Janus Henderson Group PLC raised its stake in shares of LeMaitre Vascular by 30.5% during the 3rd quarter. Janus Henderson Group PLC now owns 194,891 shares of the medical instruments supplier’s stock valued at $7,293,000 after purchasing an additional 45,586 shares during the period. Allianz Asset Management GmbH raised its stake in shares of LeMaitre Vascular by 8.2% during the 4th quarter. Allianz Asset Management GmbH now owns 348,087 shares of the medical instruments supplier’s stock valued at $11,083,000 after purchasing an additional 26,267 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of LeMaitre Vascular by 124.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 65,477 shares of the medical instruments supplier’s stock valued at $2,451,000 after purchasing an additional 36,342 shares during the period. Finally, First Mercantile Trust Co. raised its stake in shares of LeMaitre Vascular by 74.0% during the 4th quarter. First Mercantile Trust Co. now owns 8,436 shares of the medical instruments supplier’s stock valued at $269,000 after purchasing an additional 3,587 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “LeMaitre Vascular (LMAT) Sets New 1-Year High and Low at $41.19” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2018/04/17/lemaitre-vascular-lmat-sets-new-1-year-high-and-low-at-41-19.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.